VolitionRx and Sysmex Collaborate to Optimize Nu.Q NETs Assay
VolitionRx partners with Sysmex to optimize Nu.Q NETs H3.1 assay for sepsis and NETosis diseases, targeting $3.8B market. Read more at BioMedWire.
This collaboration matters because it accelerates the development of a diagnostic test that could improve early detection and monitoring of sepsis and other NETosis-related diseases, potentially saving lives and reducing healthcare costs. By leveraging Sysmex's global platform, Volition's technology could reach patients faster, addressing a $3.8 billion market opportunity and transforming patient outcomes.